PYTX 002
Alternative Names: PYTX-002Latest Information Update: 31 Oct 2022
Price :
$50 *
At a glance
- Originator Oxford BioMedica; Papyrus Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Protein replacements; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Ovarian cancer
Most Recent Events
- 20 Oct 2022 Early research in Ovarian cancer in United Kingdom (Parenteral), prior to October 2022 (Papyrus Therapeutics pipeline, October 2022).
- 10 Oct 2022 Early research in Ovarian cancer in USA (Parenteral), prior to October 2022 (Papyrus Therapeutics pipeline, October 2022).
- 10 Oct 2022 Papyrus Therapeutics plans development candidate selection in the first half of 2023 (Papyrus Therapeutics pipeline, October 2022).